Johnson & Johnson Acquires Numab’s Investigational Antibody for the Treatment of Atopic Dermatitis
The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion.
The acquisition of a novel therapy for atopic dermatitis includes an all-cash transaction totaling approximately $1.25 billion.